The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
04 Aug 2023
04 Aug 2023
Historique:
received:
21
09
2022
accepted:
11
07
2023
medline:
5
8
2023
pubmed:
5
8
2023
entrez:
4
8
2023
Statut:
epublish
Résumé
Immune-based checkpoint therapy has made significant progress in cancer treatment, but its therapeutic effect is limited. A replication-defective adenovirus (Ad) vaccine encoding tumor antigen carbonic anhydrase IX (CAIX) combined with Ad-encoding immune checkpoint PD-L1 was developed to treat renal carcinoma. Three tumor models, subcutaneous, lung metastasis and orthotopic tumor were established, and Ad vaccines were used to immunize them and evaluate the vaccine's therapeutic effect. Compared to the single Ad vaccine group, the subcutaneous tumor growth was significantly reduced in Ad-CAIX/Ad-PD-L1 combination group. Co-immunization of Ad-CAIX/Ad-PD-L1 enhanced the induction and maturation of CD11c
Identifiants
pubmed: 37542081
doi: 10.1038/s41541-023-00706-x
pii: 10.1038/s41541-023-00706-x
pmc: PMC10403580
doi:
Types de publication
Journal Article
Langues
eng
Pagination
109Subventions
Organisme : National Natural Science Foundation of China (National Science Foundation of China)
ID : 82072814
Organisme : Natural Science Research of Jiangsu Higher Education Institutions of China
ID : 22KJA320004
Organisme : Natural Science Research of Jiangsu Higher Education Institutions of China
ID : 20KJD32008
Organisme : Natural Science Research of Jiangsu Higher Education Institutions of China
ID : 19KJB310001
Informations de copyright
© 2023. Springer Nature Limited.
Références
Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Primers 3, 17009 (2017).
pubmed: 28276433
pmcid: 5936048
Deleuze, A. et al. Immunotherapy in renal cell carcinoma: the future is now. Int. J. Mol. Sci. 21, 2532 (2020).
pubmed: 32260578
pmcid: 7177761
Wolf, M. M., Kimryn Rathmell, W. & Beckermann, K. E. Modeling clear cell renal cell carcinoma and therapeutic implications. Oncogene 39, 3413–3426 (2020).
pubmed: 32123314
pmcid: 7194123
Bedke, J., Stühler, V., Stenzl, A. & Brehmer, B. Immunotherapy for kidney cancer: status quo and the future. Curr. Opin. Urol. 28, 8–14 (2018).
pubmed: 29120911
Díaz-Montero, C. M., Rini, B. I. & Finke, J. H. The immunology of renal cell carcinoma. Nat. Rev. Nephrol. 16, 721–735 (2020).
pubmed: 32733094
Harshman, L. C., Drake, C. G. & Choueiri, T. K. PD-1 blockade in renal cell carcinoma: to equilibrium and beyond. Cancer Immunol. Res. 2, 1132–1141 (2014).
pubmed: 25480555
pmcid: 4695990
Lopes, A., Vandermeulen, G. & Préat, V. Cancer DNA vaccines: current preclinical and clinical developments and future perspectives. J. Exp. Clin. Cancer Res. 38, 146 (2019).
pubmed: 30953535
pmcid: 6449928
Yang, B., Jeang, J., Yang, A., Wu, T. C. & Hung, C. F. DNA vaccine for cancer immunotherapy. Hum. Vaccin Immunother. 10, 3153–3164 (2014).
pubmed: 25625927
Hobernik, D. & Bros, M. DNA vaccines-how far from clinical use? Int. J. Mol. Sci. 19, 3605 (2018).
pubmed: 30445702
pmcid: 6274812
Zhu, F. C. et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 395, 1845–1854 (2020).
pubmed: 32450106
pmcid: 7255193
D’Alise, A. M. et al. Adenoviral vaccine targeting multiple neoantigens as strategy to eradicate large tumors combined with checkpoint blockade. Nat. Commun. 10, 2688 (2019).
pubmed: 31217437
pmcid: 6584502
Coughlan, L. Factors which contribute to the immunogenicity of non-replicating adenoviral vectored vaccines. Front Immunol. 11, 909 (2020).
pubmed: 32508823
pmcid: 7248264
Zhang, W., Fu, J. & Ehrhardt, A. Novel vector construction based on alternative adenovirus types via homologous recombination. Hum. Gene Ther. Methods 29, 124–134 (2018).
pubmed: 29756505
Duffy, M. R. et al. Generation and characterization of a novel candidate gene therapy and vaccination vector based on human species D adenovirus type 56. J. Gen. Virol. 99, 135–147 (2018).
pubmed: 29154744
Xiang, Z. Q., Yang, Y., Wilson, J. M. & Ertl, H. C. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219, 220–227 (1996).
pubmed: 8623532
Tatsis, N. et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110, 1916–1923 (2007).
pubmed: 17510320
pmcid: 1976365
Bassett, J. D. et al. CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood 117, 1146–1155 (2011).
pubmed: 21088134
Yang, T. C., Dayball, K., Wan, Y. H. & Bramson, J. Detailed analysis of the CD8+ T-cell response following adenovirus vaccination. J. Virol. 77, 13407–13411 (2003).
pubmed: 14645597
pmcid: 296052
Sullivan, N. J. et al. CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat. Med. 17, 1128–1131 (2011).
pubmed: 21857654
Barouch, D. H. et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet 392, 232–243 (2018).
pubmed: 30047376
pmcid: 6192527
Courcier, J. et al. Carbonic anhydrase IX in renal cell carcinoma, implications for disease management. Int. J. Mol. Sci. 21, 7146 (2020).
pubmed: 32998233
pmcid: 7582814
Stillebroer, A. B., Mulders, P. F., Boerman, O. C., Oyen, W. J. & Oosterwijk, E. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. Eur. Urol. 58, 75–83 (2010).
pubmed: 20359812
van Kuijk, S. J. et al. Prognostic significance of carbonic anhydrase IX expression in cancer patients: a meta-analysis. Front Oncol. 6, 69 (2016).
pubmed: 27066453
pmcid: 4810028
Oosterwijk-Wakka, J. C., Boerman, O. C., Mulders, P. F. & Oosterwijk, E. Application of monoclonal antibody G250 recognizing carbonic anhydrase IX in renal cell carcinoma. Int. J. Mol. Sci. 14, 11402–11423 (2013).
pubmed: 23759990
pmcid: 3709739
Zhao, Y. et al. Enhance the anti-renca carcinoma effect of a DNA vaccine targeting G250 gene by co-expression with cytotoxic T-lymphocyte associated antigen-4(CTLA-4). Biomed. Pharmacother. 90, 147–152 (2017).
pubmed: 28351777
Li, T. R. et al. Effective inhibition of tumor in vivo with a novel DNA vaccine targeting chimeric G250. Eur. Rev. Med. Pharmacol. Sci. 24, 7454–G7461 (2020).
pubmed: 32706085
Faiena, I. et al. A phase I, open-label, dose-escalation, and cohort expansion study to evaluate the safety and immune response to autologous dendritic cells transduced with AdGMCA9 (DC-AdGMCAIX) in patients with metastatic renal cell carcinoma. J. Immunother. 43, 273–282 (2020).
pubmed: 32925563
Chai, D. et al. Co-immunization with L-Myc enhances CD8(+) or CD103(+) DCs mediated tumor-specific multi-functional CD8(+) T cell responses. Cancer Sci. 112, 3469–3483 (2021).
pubmed: 34157192
pmcid: 8409417
Chai, D. et al. Combining DNA vaccine and AIM2 in H1 nanoparticles exert anti-renal carcinoma effects via enhancing tumor-specific multi-functional CD8(+) T-cell responses. Mol. Cancer Ther. 18, 323–334 (2019).
pubmed: 30401695
Vissers, J. L. et al. Renal cell carcinoma-associated antigen G250 encodes a naturally processed epitope presented by human leukocyte antigen-DR molecules to CD4(+) T lymphocytes. Int. J. Cancer 100, 441–444 (2002).
pubmed: 12115527
Sun, Z., Liu, B., Ruan, X. & Liu, Q. An enhanced immune response against G250, induced by a heterologous DNA prime‑protein boost vaccination, using polyethyleneimine as a DNA vaccine adjuvant. Mol. Med. Rep. 10, 2657–2662 (2014).
pubmed: 25190325
Chen, J. et al. A Novel Anti-PD-L1 Vaccine for Cancer Immunotherapy and Immunoprevention. Cancers (Basel) 11, 1909 (2019).
pubmed: 31805690
Kammerer-Jacquet, S. F. et al. Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. Int. J. Mol. Sci. 20, 1692 (2019).
pubmed: 30987368
pmcid: 6480014
Latchman, Y. E. et al. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proc. Natl Acad. Sci. USA 101, 10691–10696 (2004).
pubmed: 15249675
pmcid: 489996
Zhang, C. et al. B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncol. Rep. 30, 2442–2448 (2013).
pubmed: 23970300
Guo, S. et al. Co-immunizing with PD-L1 induces CD8(+) DCs-mediated anti-tumor immunity in multiple myeloma. Int. Immunopharmacol. 84, 106516 (2020).
pubmed: 32334387
Tian, H. et al. PDL1-targeted vaccine exhibits potent antitumor activity by simultaneously blocking PD1/PDL1 pathway and activating PDL1-specific immune responses. Cancer Lett 476, 170–182 (2020).
pubmed: 32092355
Shaw, A. R. & Suzuki, M. Immunology of adenoviral vectors in cancer therapy. Mol. Ther. Methods Clin. Dev. 15, 418–429 (2019).
pubmed: 31890734
pmcid: 6909129
Sharma, P. & Allison, J. P. The future of immune checkpoint therapy. Science 348, 56–61 (2015).
pubmed: 25838373
Lin, Z. et al. A PD-L1-based cancer vaccine elicits antitumor immunity in a mouse melanoma model. Mol. Ther. Oncolytics 14, 222–232 (2019).
pubmed: 31384666
pmcid: 6667823
Ahmad, S. M., Borch, T. H., Hansen, M. & Andersen, M. H. PD-L1-specific T cells. Cancer Immunol. Immunother. 65, 797–804 (2016).
pubmed: 26724936
Desch, A. N. et al. Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction. Nat. Commun. 5, 4674 (2014).
pubmed: 25135627
Li, L. et al. Cross-dressed CD8α+/CD103+ dendritic cells prime CD8+ T cells following vaccination. Proc. Natl Acad. Sci. USA 109, 12716–12721 (2012).
pubmed: 22802630
pmcid: 3411977